These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 21134050)

  • 1. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications.
    Dressler D; Wohlfahrt K; Meyer-Rogge E; Wiest L; Bigalke H
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2182-7. PubMed ID: 21134050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical resistance to three types of botulinum toxin type A in aesthetic medicine.
    Stephan F; Habre M; Tomb R
    J Cosmet Dermatol; 2014 Dec; 13(4):346-8. PubMed ID: 25399628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of pachydermoperiostosis pachydermia with botulinum toxin type A.
    Ghosn S; Uthman I; Dahdah M; Kibbi AG; Rubeiz N
    J Am Acad Dermatol; 2010 Dec; 63(6):1036-41. PubMed ID: 20933299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type a for facial rejuvenation: treatment evolution and patient satisfaction.
    Sepehr A; Chauhan N; Alexander AJ; Adamson PA
    Aesthetic Plast Surg; 2010 Oct; 34(5):583-6. PubMed ID: 20383497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facial rejuvenation after intradermal botulinum toxin: is it really the botulinum toxin or is it the pricks?
    Kapoor R; Shome D; Jain V; Dikshit R
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2098-105. PubMed ID: 21134041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation.
    Carruthers A; Carruthers J; Monheit GD; Davis PG; Tardie G
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2121-34. PubMed ID: 21134044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
    Sattler G; Callander MJ; Grablowitz D; Walker T; Bee EK; Rzany B; Flynn TC; Carruthers A
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2146-54. PubMed ID: 21134045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of botulinum toxin type A in cosmetic facial procedures.
    Jaspers GW; Pijpe J; Jansma J
    Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow's feet.
    Guerrissi JO
    Plast Reconstr Surg; 2003 Oct; 112(5 Suppl):161S-163S. PubMed ID: 14504499
    [No Abstract]   [Full Text] [Related]  

  • 10. Cosmetic indications for botulinum A toxin.
    Foster JA; Wulc AE; Holck DE
    Semin Ophthalmol; 1998 Sep; 13(3):142-8. PubMed ID: 9787215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications.
    Borodic G
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):11-6, v. PubMed ID: 17317551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines.
    Brandt F; O'Connell C; Cazzaniga A; Waugh JM
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2111-8. PubMed ID: 21134043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes.
    Carruthers J; Carruthers A; Monheit GD; Davis PG
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2135-45. PubMed ID: 21070457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IncobotulinumtoxinA in esthetics.
    Kerscher M; Yutskovskaya Y; Flynn TC
    J Drugs Dermatol; 2013 Jun; 12(6):e111-20. PubMed ID: 23839200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study.
    Prager W; Wissmüller E; Kollhorst B; Williams S; Zschocke I
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2155-60. PubMed ID: 21134046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective rating of cosmetic treatment with botulinum toxin type A: do existing measures demonstrate interobserver validity?
    Conkling N; Bishawi M; Phillips BT; Bui DT; Khan SU; Dagum AB
    Ann Plast Surg; 2012 Oct; 69(4):350-5. PubMed ID: 22964674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary: Efficacy and safety of a novel botulinum toxin topical gel.
    West TB
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2119-20. PubMed ID: 21244565
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines.
    Stengel G; Bee EK
    Clin Interv Aging; 2011; 6():281-4. PubMed ID: 22162643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical aspects of cosmetic botulinum toxin.
    Mannor GE
    Int Ophthalmol Clin; 2005; 45(3):99-106. PubMed ID: 15970769
    [No Abstract]   [Full Text] [Related]  

  • 20. Addressing recent concerns in comparative studies of botulinum toxin type A.
    de Boulle K; de Almeida AT
    J Cosmet Laser Ther; 2010 Oct; 12(5):246-8. PubMed ID: 20825255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.